-
公开(公告)号:US5461067A
公开(公告)日:1995-10-24
申请号:US185666
申请日:1994-02-01
Applicant: Daniel W. Norbeck , Hing L. Sham , Dale J. Kempf , Chen Zhao
Inventor: Daniel W. Norbeck , Hing L. Sham , Dale J. Kempf , Chen Zhao
IPC: A61K31/42 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4418 , A61P35/00 , A61P43/00 , C07C281/02 , C07C281/06 , C07D213/30 , C07D213/38 , C07D213/40 , C07D261/08 , C07D263/32 , C07D265/30 , C07D275/02 , C07D277/24 , C07D277/28 , C07D307/52 , C07D309/04 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D263/30 , C07D277/20
CPC classification number: C07D213/30 , C07C281/02 , C07C281/06 , C07D213/38 , C07D213/40 , C07D261/08 , C07D263/32 , C07D265/30 , C07D275/02 , C07D277/24 , C07D277/28 , C07D307/52 , C07D309/04 , C07D405/12 , C07D413/12 , C07D417/12 , C07C2101/14
Abstract: A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed wherein R.sub.1, R.sub.2, R.sub.5, R.sub.6, Y.sub.m and Y'.sub.n are herein defined.
Abstract translation: 公开了下式的逆转录病毒蛋白酶抑制化合物:其中R1,R2,R5,R6,Ym和Y'n在本文中定义。
-
公开(公告)号:US5268374A
公开(公告)日:1993-12-07
申请号:US700185
申请日:1991-05-22
Applicant: Anthony K. L. Fung , William R. Baker , Yoek-Lin Armiger , Saul H. Rosenberg , Biswanath De , Jacob J. Plattner , Steven A. Boyd , Dale J. Kempf , Hing L. Sham , Hollis D. Kleinert , Robert A. Mantei
Inventor: Anthony K. L. Fung , William R. Baker , Yoek-Lin Armiger , Saul H. Rosenberg , Biswanath De , Jacob J. Plattner , Steven A. Boyd , Dale J. Kempf , Hing L. Sham , Hollis D. Kleinert , Robert A. Mantei
IPC: C07C237/08 , C07C317/28 , C07C323/58 , C07D203/18 , C07D211/44 , C07D211/62 , C07D211/96 , C07D233/54 , C07D295/185 , C07D401/12 , C07D407/12 , C07D413/12 , A61K37/43 , C07K5/08
CPC classification number: C07D233/64 , C07C237/08 , C07C317/28 , C07C323/58 , C07D203/18 , C07D211/44 , C07D211/62 , C07D211/96 , C07D295/185 , C07D401/12 , C07D407/12 , C07D413/10 , C07C2101/14
Abstract: The present invention relates to renin inhibiting compounds of the formula: ##STR1##
Abstract translation: 本发明涉及下式的肾素抑制化合物:
-
33.Compositions and methods of use of ritonavir for treating HCV 有权
Title translation: 利托那韦治疗HCV的组合物和使用方法公开(公告)号:US08901157B2
公开(公告)日:2014-12-02
申请号:US12958899
申请日:2010-12-02
Applicant: Dale J. Kempf , Kennan C. Marsh
Inventor: Dale J. Kempf , Kennan C. Marsh
IPC: A61K31/407 , A61K31/4965 , A61K31/497 , A61K38/21 , A61K31/403 , A61K31/7056
CPC classification number: A61K38/212 , A61K31/407 , A61K31/4965 , A61K31/497 , A61K31/7056 , A61K2300/00
Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.
Abstract translation: 本发明公开了通过包含联合利托那韦或其药学上可接受的盐,酯和前药的细胞色素P450单加氧酶代谢的药物(或其药学上可接受的盐,酯和前体药物)的药代动力学的组合物和方法。
-
公开(公告)号:US08426388B2
公开(公告)日:2013-04-23
申请号:US12756084
申请日:2010-04-07
Applicant: David A. DeGoey , William J. Flosi , David J. Grampovnik , Larry L. Klein , Dale J. Kempf , Xiu C. Wang
Inventor: David A. DeGoey , William J. Flosi , David J. Grampovnik , Larry L. Klein , Dale J. Kempf , Xiu C. Wang
IPC: C07F9/09 , A61K31/661
CPC classification number: A61K45/06 , A61K31/661 , A61K2300/00
Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.
Abstract translation: 公开了式的化合物作为HIV蛋白酶抑制剂的前药。 还公开了用于抑制HIV蛋白酶活性和治疗HIV感染的方法和组合物。
-
公开(公告)号:US20130023463A1
公开(公告)日:2013-01-24
申请号:US13451370
申请日:2012-04-19
Applicant: Charles A. Flentge , Hui-Ju Chen , David A. DeGoey , William J. Flosi , David J. Grampovnik , Peggy P. Huang , Dale J. Kempf , Larry L. Klein , Allan C. Krueger , Darold L. Madigan , John T. Randolph , Minghua Sun , Ming C. Yeung , Chen Zhao
Inventor: Charles A. Flentge , Hui-Ju Chen , David A. DeGoey , William J. Flosi , David J. Grampovnik , Peggy P. Huang , Dale J. Kempf , Larry L. Klein , Allan C. Krueger , Darold L. Madigan , John T. Randolph , Minghua Sun , Ming C. Yeung , Chen Zhao
IPC: A61K31/18 , C07D213/53 , A61K31/4402 , C07D307/14 , A61K31/341 , A61K31/4418 , C07D307/52 , C07D277/30 , A61K31/426 , C07C275/24 , A61K31/197 , C07D213/86 , C07D493/04 , A61K31/34 , C07D333/20 , A61K31/381 , C07C275/16 , A61P31/18 , A61K31/513 , A61K31/496 , A61K31/7072 , A61K31/708 , A61K38/16 , C12N9/99 , C07C311/37
CPC classification number: C07D417/12 , C07C311/18 , C07C311/29 , C07C311/41 , C07C311/47 , C07C317/18 , C07D209/14 , C07D213/30 , C07D213/40 , C07D233/36 , C07D233/64 , C07D233/72 , C07D277/24 , C07D277/28 , C07D307/14 , C07D307/20 , C07D307/52 , C07D333/20 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/10 , C07D409/06 , C07D409/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D493/04
Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Abstract translation: 公开了式的化合物作为HIV蛋白酶抑制剂。 还公开了用于抑制HIV感染的方法和组合物。
-
公开(公告)号:US08338605B2
公开(公告)日:2012-12-25
申请号:US12817808
申请日:2010-06-17
Applicant: Todd W. Rockway , David A. Betebenner , Allan C. Krueger , Nobuhiko Iwasaki , Curt S. Cooper , David D. Anderson , Dale J. Kempf , Darold L. Madigan , Christopher E. Motter , Jason P. Shanley , Michael D. Tufano , Rolf Wagner , Rong Zhang , Akteruzzaman Molla , Hongmei Mo , Tami J. Pilot-Matias , Sherie V. L. Masse , Robert J. Carrick , Wenping He , Liangjun Lu
Inventor: Todd W. Rockway , David A. Betebenner , Allan C. Krueger , Nobuhiko Iwasaki , Curt S. Cooper , David D. Anderson , Dale J. Kempf , Darold L. Madigan , Christopher E. Motter , Jason P. Shanley , Michael D. Tufano , Rolf Wagner , Rong Zhang , Akteruzzaman Molla , Hongmei Mo , Tami J. Pilot-Matias , Sherie V. L. Masse , Robert J. Carrick , Wenping He , Liangjun Lu
IPC: C07D471/02
CPC classification number: C07D471/04
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
Abstract translation: 公开了有效抑制丙型肝炎病毒(HCV)或其他病毒复制的化合物。 本发明还涉及包含这些化合物的组合物,这些化合物与其它抗病毒剂或治疗剂的共同配制或共同给药,用于合成这些化合物的方法和中间体,以及使用这些化合物治疗 HCV或其他病毒感染。
-
公开(公告)号:US20120309762A1
公开(公告)日:2012-12-06
申请号:US13587516
申请日:2012-08-16
Applicant: Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
Inventor: Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
IPC: C07D277/24 , C07D417/12 , A61K31/4439 , A61K31/426 , A61K31/427 , A61P31/12 , C07D417/14 , A61K31/5355 , A61K31/496 , A61K31/5377 , A61K31/454 , C12N9/99 , A61K31/513
CPC classification number: A61K31/5377 , A61K31/4164 , A61K31/4178 , A61K31/4439 , A61K31/4525 , A61K31/496 , A61K31/506 , A61K45/06 , C07D213/79 , C07D277/24 , C07D277/30 , C07D277/593 , C07D417/12
Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
-
38.
公开(公告)号:US08133892B2
公开(公告)日:2012-03-13
申请号:US12834315
申请日:2010-07-12
Applicant: Dale J. Kempf
Inventor: Dale J. Kempf
IPC: A61K31/497 , A61K31/415 , C07D241/04 , C07D233/02
CPC classification number: C07D277/30 , A61K31/426 , A61K31/427 , A61K45/06 , C07C53/18 , C07D213/30 , C07D231/12 , C07D233/64 , C07D263/32 , C07D277/24 , C07D277/38 , C07D277/587 , C07D333/16 , C07D417/04
Abstract: Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.
Abstract translation: 新的式1化合物或其药学上可接受的盐抑制细胞色素P450单加氧酶。
-
公开(公告)号:US20100286032A1
公开(公告)日:2010-11-11
申请号:US12756084
申请日:2010-04-07
Applicant: David A. DeGoey , William J. Flosi , David J. Grampovnik , Larry L. Klein , Dale J. Kempf , Xiu C. Wang
Inventor: David A. DeGoey , William J. Flosi , David J. Grampovnik , Larry L. Klein , Dale J. Kempf , Xiu C. Wang
IPC: A61K38/13 , C07D277/30 , A61K31/427 , A61K31/675 , C07D239/10 , A61K31/513 , A61K31/7072 , A61K31/4709 , A61K31/4985 , A61P31/18
CPC classification number: A61K45/06 , A61K31/661 , A61K2300/00
Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.
Abstract translation: 公开了式的化合物作为HIV蛋白酶抑制剂的前药。 还公开了用于抑制HIV蛋白酶活性和治疗HIV感染的方法和组合物。
-
40.Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate 审中-公开
Title translation: 治疗由UGT1A1基质升高的血清浓度引起的疾病,障碍或不良反应的方法公开(公告)号:US20100261731A1
公开(公告)日:2010-10-14
申请号:US12422434
申请日:2009-04-13
Applicant: Dale J. Kempf , Richard J. Bertz , Jeffrey F. Waring
Inventor: Dale J. Kempf , Richard J. Bertz , Jeffrey F. Waring
IPC: A61K31/496 , A61K31/426 , A61P31/18 , A61K31/4402
CPC classification number: A61K31/426 , A61K9/08 , A61K31/4402 , A61K31/496 , A61K45/06 , A61K47/10 , A61K2300/00
Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
Abstract translation: 本发明涉及一种用于诱导UGT1A1同种型表达的方法,用于治疗由UGT1A1底物升高的血清浓度引起的疾病,障碍或不良反应,包括向受试者施用有效量的利托那韦的步骤。 特别地,本发明涉及一种通过UGT1A1诱导处理未结合的高胆红素血症的方法,其包括向受试者施用有效量的利托那韦的步骤。
-
-
-
-
-
-
-
-
-